Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection

Human Genetics

Volumn 131, Issue 12, 2012, Pages 1911-1920

  Chiba Falek, Ornit ^a,b   Linnertz, Colton ^a   Guyton, John ^a   Gardner, Stephen D ^c   Roses, Allen D ^a,b,d   McCarthy, Jeanette J ^a   Patel, Keyur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Zinfandel Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 28B; LIPID; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHROMOSOME 19; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; FIBROSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PRIORITY JOURNAL;

ADULT; AFRICAN AMERICANS; APOLIPOPROTEIN C-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; CHOLESTEROL, LDL; COHORT STUDIES; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

HEPATITIS C VIRUS;

EID: 84871009688     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-012-1220-0     Document Type: Article

References (52)

1. Allan CM, Taylor S, Taylor JM (1997) Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 272:29113-29119
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714
4. Balagopal A, Thomas DL, Thio CL (2010) IL28B and the control of hepatitis C virus infection. Gastroenterology 139:1865-1876
5. Barrett JC (2009) Haploview: Visualization and analysis of SNP genotype data. Cold Spring Harb Protoc 2009:pdb.ip71
6. Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis C virus particles. Trends Microbiol 19:95-103
7. Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, Yu CE (2008) Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis 13:255-266
8. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE (2010) APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 153B:409-417
9. Bekris LM, Lutz F, Yu CE (2012) Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. J Hum Genet 57:18-25
10. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298:1300-1311
11. Boerwinkle E, Utermann G (1988) Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 42:104-112
12. Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, Petrarca A, Solazzo V, Monti M, Laffi G, Zignego AL (2007) Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection. J Viral Hepat 14:22-28
13. Cun W, Jiang J, Luo G (2010) The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus. J Virol 84:11532-11541
14. Dai C, Chuang W, Ho C et al (2008) Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. J Hepatol 49:9-16
15. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Pare G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M, Smith NL, Smith AV, Sundvall J, Scheet P, Liu Y, Ruokonen A, Rose LM, Larson MG, Hoogeveen RC, Freimer NB, Teumer A, Tracy RP, Launer LJ, Buring JE, Yamamoto JF, Folsom AR, Sijbrands EJ, Pankow J, Elliott P, Keaney JF, Sun W, Sarin AP, Fontes JD, Badola S, Astor BC, Hofman A, Pouta A, Werdan K, Greiser KH, Kuss O, Meyer zu Schwabedissen HE, Thiery J, Jamshidi Y, Nolte IM, Soranzo N, Spector TD, Volzke H, Parker AN, Aspelund T, Bates D, Young L, Tsui K, Siscovick DS, Guo X, Rotter JI, Uda M, Schlessinger D, Rudan I, Hicks AA, Penninx BW, Thorand B, Gieger C, Coresh J, Willemsen G, Harris TB, Uitterlinden AG, Jarvelin MR, Rice K, Radke D, Salomaa V, Willems van Dijk K, Boerwinkle E, Vasan RS, Ferrucci L, Gibson QD, Bandinelli S, Snieder H, Boomsma DI, Xiao X, Campbell H et al (2011) Meta-analysis of genome-wide association studies in[80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123:731-738
16. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E (2008) Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 23:586-591
17. Enjoji M, Nakamuta M, Kinukawa N (2000) Beta-lipoproteins influence the serum level of hepatitis c virus. Med Sci Monit 6:841-844
18. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M (1997) Blood lipids of patients with chronic hepatitis: Differences related to viral etiology. Clin Chim Acta 261:159-165
19. Fabris C, Vandelli C, Toniutto P, Minisini R, Colletta C, Falleti E, Smirne C, Pirisi M (2011) Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Gastroenterol Hepatol 26:328-333
20. Fernandez-Rodriguez C, Lopez-Serrano P, Alonso S (2006) Longterm reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 24:507-512
21. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC Jr, Min AD (2006) Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:335-340
22. Grigorescu M, Rusu M, Neculoiu D, Radu C, Serban A, Catanas M, Grigorescu MD (2007) The fibrotest value in discriminatingbetween insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian Experience. J Gastrointestin Liver Dis 16:31-37
23. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA (2011) A Catalog of PublishedGenome-Wide Association Studies.Available at: Http://www.genome.gov/ gwastudies. Accessed May 18 2011
24. Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K (2010) Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol 84:12048-12057
25. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S (2010) Hepatic interferon-stimulated genes expression is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C. Gastroenterology 139:499-509
26. Humphries AD, Streimann IC, Stojanovski D, Johnston AJ, Yano M, Hoogenraad NJ, Ryan MT (2005) Dissection of the mitochondrial import and assembly pathway for human Tom40. J Biol Chem 280:11535-11543
27. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 357:1069-1075
28. Jarmay K, Karacsony G, Nagy A, Schaff Z (2005) Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 11:6422-6428
29. Lao XQ, Thompson A, McHutchison JG, McCarthy JJ (2010) Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. J Viral Hepat 18:571-579
30. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, Muir AJ, Guyton JR, Gardner SD, McHutchison JG, McCarthy JJ (2010) Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51:1904-1911
31. Linnertz C, Saunders AM, Lutz MW, Crenshaw DM, Grossman I, Burns DK, Whitfield KE, Hauser MA, McCarthy JJ, Ulmer M, Allingham R, Welsh-Bohmer KA, Roses AD, Chiba-Falek O (2012) Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations. PLoS ONE 7:e30994
32. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 50 nuclease assay. Genet Anal 14:143-149
33. Lutz MW, Crenshaw DG, Saunders AM, Roses AD (2010) Genetic variation at a single locus and age of onset for Alzheimer's disease. Alzheimers Dement 6:125-131
34. Marzouk D, Sass J, Bakr I (2007) Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 56:1105-1110
35. McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S (2010) Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 138:1365-1373, 1373.e1-2. doi:10.1053/j.gastro.2009.12.003
36. Minuk GY, Weinstein S, Kaita KD (2000) Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C. Ann Intern Med 132:761-762
37. Moriya K, Shintani Y, Fujie H (2003) Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 25:371-376
38. Mueller T, Gessner R, Sarrazin C, Graf C, Halangk J, Witt H, Kottgen E, Wiedenmann B, Berg T (2003) Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology 38:1592; author reply 1592-1593
39. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T (2003) Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 17:721-725
40. Petit J, Benichou M, Duvillard L et al (2003a) Hepatitis C virusassociated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 98:1150-1154
41. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A, Verges B, Brun JM, Gambert P, Hillon P (2003b) Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 98:1150-1154
42. Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, Burt AD, Donaldson PT (2006) Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 55:715-718
43. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10:375-384
44. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472
45. Serfay L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R (2001) Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428-433
46. Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamin A, Rowell J, Ginsburg GS, McCarthy JJ (2010) Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 6:e1000928
47. Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Mariuzzi L, Avellini C, Minisini R, Pirisi M (2004) Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment. Am J Clin Pathol 122:428-433
48. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV, McHutchison JG, Goldstein DB, Afdhal N (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888-1896
49. Weisgraber KH, Innerarity TL, Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:2518-2521
50. Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, Sulat-Syncerek D (2006) Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology 53:887-891
51. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL (2002) Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36:456-463
52. Ye J (2007) Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog 3:e108